JP4796967B2 - アルツハイマー病のためのバイオマーカー - Google Patents

アルツハイマー病のためのバイオマーカー Download PDF

Info

Publication number
JP4796967B2
JP4796967B2 JP2006538558A JP2006538558A JP4796967B2 JP 4796967 B2 JP4796967 B2 JP 4796967B2 JP 2006538558 A JP2006538558 A JP 2006538558A JP 2006538558 A JP2006538558 A JP 2006538558A JP 4796967 B2 JP4796967 B2 JP 4796967B2
Authority
JP
Japan
Prior art keywords
biomarker
alzheimer
cystatin
disease
peptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2006538558A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007524847A (ja
JP2007524847A5 (enExample
Inventor
ヒュー アラン デイビス，
ジェイムス マグァイア，
アンジャ フヴィッド シモンセン，
カイ ブレンナウ，
ヴラディミール ポドスト，
Original Assignee
ヴァーミリオン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヴァーミリオン インコーポレイテッド filed Critical ヴァーミリオン インコーポレイテッド
Publication of JP2007524847A publication Critical patent/JP2007524847A/ja
Publication of JP2007524847A5 publication Critical patent/JP2007524847A5/ja
Application granted granted Critical
Publication of JP4796967B2 publication Critical patent/JP4796967B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6842—Proteomic analysis of subsets of protein mixtures with reduced complexity, e.g. membrane proteins, phosphoproteins, organelle proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G01N33/6851—Methods of protein analysis involving laser desorption ionisation mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Optics & Photonics (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
JP2006538558A 2003-11-07 2004-11-06 アルツハイマー病のためのバイオマーカー Expired - Fee Related JP4796967B2 (ja)

Applications Claiming Priority (15)

Application Number Priority Date Filing Date Title
US51836003P 2003-11-07 2003-11-07
US60/518,360 2003-11-07
US52675303P 2003-12-02 2003-12-02
US60/526,753 2003-12-02
US54642304P 2004-02-19 2004-02-19
US60/546,423 2004-02-19
US54725004P 2004-02-23 2004-02-23
US60/547,250 2004-02-23
US55889604P 2004-04-02 2004-04-02
US60/558,896 2004-04-02
US57261704P 2004-05-18 2004-05-18
US60/572,617 2004-05-18
US58650304P 2004-07-08 2004-07-08
US60/586,503 2004-07-08
PCT/US2004/037994 WO2005047484A2 (en) 2003-11-07 2004-11-06 Biomarkers for alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011012368A Division JP5479379B2 (ja) 2003-11-07 2011-01-24 アルツハイマー病のためのバイオマーカー

Publications (3)

Publication Number Publication Date
JP2007524847A JP2007524847A (ja) 2007-08-30
JP2007524847A5 JP2007524847A5 (enExample) 2011-03-10
JP4796967B2 true JP4796967B2 (ja) 2011-10-19

Family

ID=34596275

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006538558A Expired - Fee Related JP4796967B2 (ja) 2003-11-07 2004-11-06 アルツハイマー病のためのバイオマーカー
JP2011012368A Expired - Fee Related JP5479379B2 (ja) 2003-11-07 2011-01-24 アルツハイマー病のためのバイオマーカー

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011012368A Expired - Fee Related JP5479379B2 (ja) 2003-11-07 2011-01-24 アルツハイマー病のためのバイオマーカー

Country Status (4)

Country Link
US (2) US7794948B2 (enExample)
EP (3) EP2369348A1 (enExample)
JP (2) JP4796967B2 (enExample)
WO (1) WO2005047484A2 (enExample)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
US7707134B2 (en) * 2005-01-14 2010-04-27 Siemens Medical Solutions Usa, Inc. System and method for molecular diagnosis of depression based on boosting classification
FR2882171A1 (fr) * 2005-02-14 2006-08-18 France Telecom Procede et dispositif de generation d'un arbre de classification permettant d'unifier les approches supervisees et non supervisees, produit programme d'ordinateur et moyen de stockage correspondants
JP5147684B2 (ja) * 2005-04-06 2013-02-20 モザイクヴェス ディアグノシュティクス アンド テラポイティクス アクチェン ゲゼルシャフト アルツハイマー病の診断のためのポリペプチドマーカー
US9335331B2 (en) * 2005-04-11 2016-05-10 Cornell Research Foundation, Inc. Multiplexed biomarkers for monitoring the Alzheimer's disease state of a subject
JP2008546701A (ja) * 2005-06-14 2008-12-25 イェシバ・ユニバーシティ Ａβ産生へのＢＲＩ蛋白の効果
JP2008547003A (ja) * 2005-06-16 2008-12-25 バーミリオン， インコーポレイテッド アルツハイマー病についてのバイオマーカーとしての神経分泌タンパク質ｖｇｆのフラグメント
WO2007012052A1 (en) * 2005-07-20 2007-01-25 Medical College Of Georgia Research Institute Use of protein profiles in disease diagnosis and treatment
EP1954718B1 (en) 2005-11-30 2014-09-03 AbbVie Inc. Anti-a globulomer antibodies, antigen-binding moieties thereof, corresponding hybridomas, nucleic acids, vectors, host cells, methods of producing said antibodies, compositions comprising said antibodies, uses of said antibodies and methods of using said antibodies
RU2432362C2 (ru) 2005-11-30 2011-10-27 Эбботт Лэборетриз Моноклональные антитела и их применения
JPWO2007105442A1 (ja) * 2006-02-22 2009-07-30 協和発酵キリン株式会社 摂食障害または摂水障害の治療薬
AU2007219666A1 (en) 2006-02-28 2007-09-07 Phenomenome Discoveries Inc. Methods for the diagnosis of dementia and other neurological disorders
JP5357746B2 (ja) * 2006-03-11 2013-12-04 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 末梢性の動脈疾患のためのバイオマーカーとしてのβ−２ミクログロブリン
WO2007136614A2 (en) * 2006-05-19 2007-11-29 Merck & Co., Inc. Assays and methods for the diagnosis and progression of alzheimer's disease using a multi-analyte marker panel
WO2007139777A2 (en) * 2006-05-26 2007-12-06 Merck & Co., Inc. Methods for the diagnosis and prognosis of alzheimer's disease using csf protein profiling
US7851172B2 (en) * 2006-07-25 2010-12-14 University Of Kentucky Research Foundation Biomarkers of mild cognitive impairment and alzheimer's disease
US20080117416A1 (en) * 2006-10-27 2008-05-22 Hunter Ian W Use of coherent raman techniques for medical diagnostic and therapeutic purposes, and calibration techniques for same
DE102006056337A1 (de) * 2006-11-29 2008-06-05 B.R.A.H.M.S Ag In vitro Verfahren zur Diagnose und Frühdiagnose von neurodegenerativen Erkrankungen
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
GB0701626D0 (en) * 2007-01-22 2007-03-07 Cambridge Entpr Ltd Methods and biomarkers for diagnosing and monitoring psychotic disorders
JP5470050B2 (ja) 2007-02-08 2014-04-16 フェノメノーム ディスカバリーズ インク アルツハイマー型老年認知症の治療方法
EP2486928A1 (en) 2007-02-27 2012-08-15 Abbott GmbH & Co. KG Method for the treatment of amyloidoses
US8481277B2 (en) 2007-08-21 2013-07-09 Washington University Alzheimer's diagnosis
WO2009114945A1 (en) 2008-03-21 2009-09-24 Neuman Manuela G Methods and kits for the differential diagnosis of alzheimer's disease versus frontotemporal dementia, and for the diagnosis of frontotemporal dementia, comprising fas-l and ckl 18 as biomarkers
DK2324360T3 (en) 2008-08-11 2018-05-14 Banyan Biomarkers Inc BIOMARKET DETECTION METHOD AND ASSAY OF NEUROLOGICAL CONDITION
US20140342381A1 (en) * 2008-08-11 2014-11-20 Banyan Biomarkers, Inc. Devices and methods for biomarker detection process and assay of neurological condition
US20110263450A1 (en) * 2008-09-26 2011-10-27 The University Of Melbourne Alzheimer's disease biomarkers
GB0818650D0 (en) 2008-10-10 2008-11-19 Uni I Oslo Methods
AU2009326857B2 (en) * 2008-12-09 2016-05-26 Stephanie Fryar-Williams Novel biomarkers
WO2010087771A1 (en) 2009-01-30 2010-08-05 Alphabeta Ab Compound and method for treatment of alzheimer's disease
WO2011005893A2 (en) * 2009-07-07 2011-01-13 Abbott Laboratories Biomarkers and methods for detecting alzheimer's disease
ES2581178T3 (es) 2009-07-29 2016-09-01 Pharnext Nuevas herramientas de diagnóstico para enfermedad de Alzheimer
US20110097747A1 (en) * 2009-10-26 2011-04-28 Kevin Jones Monoclonal antibody binds antigen associated with human tumors
WO2011130377A2 (en) 2010-04-15 2011-10-20 Abbott Laboratories Amyloid-beta binding proteins
EP3533803B1 (en) 2010-08-14 2021-10-27 AbbVie Inc. Anti-amyloid-beta antibodies
WO2012037232A2 (en) * 2010-09-16 2012-03-22 University Of Miami Compositions, methods and kits for detecting and treating alzheimer's disease
JP6012923B2 (ja) * 2010-12-22 2016-10-25 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
EP2694977B1 (en) * 2011-04-05 2016-06-29 Alphabeta AB Amyloidosis target useful in methods of screening of compounds
US20140302532A1 (en) 2011-04-12 2014-10-09 Quanterix Corporation Methods of determining a treatment protocol for and/or a prognosis of a patient's recovery from a brain injury
US9835621B2 (en) 2011-07-14 2017-12-05 University Of Kentucky Research Foundation Process for detection of alzheimer's disease from a serum sample
WO2013153461A2 (en) 2012-04-13 2013-10-17 Oasis Diagnostics Corporation Specific salivary biomarkers for risk detection, early diagnosis, prognosis and monitoring of alzheimer's and parkinson's diseases
US9678086B2 (en) 2012-09-10 2017-06-13 The Johns Hopkins University Diagnostic assay for Alzheimer's disease
US20140271463A1 (en) * 2013-03-12 2014-09-18 Stichting Vu-Vumc Bri2 as a novel biomarker for alzheimer's disease
US10806717B2 (en) * 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
WO2014183023A1 (en) 2013-05-09 2014-11-13 Trustees Of Boston University Using plexin-a4 as a biomarker and therapeutic target for alzheimer's disease
WO2015020523A1 (en) 2013-08-07 2015-02-12 Stichting Vu-Vumc Biomarkers for early diagnosis of alzheimer's disease
WO2015089375A1 (en) 2013-12-13 2015-06-18 The General Hospital Corporation Soluble high molecular weight (hmw) tau species and applications thereof
WO2015152724A2 (en) 2014-04-02 2015-10-08 Stichting Vu-Vumc Biomarkers for the detection of frontotemporal dementia
US9753036B2 (en) 2014-04-29 2017-09-05 Edp Biotech Corporation Methods and compositions for screening and detecting biomarkers
GB201504432D0 (en) * 2015-03-17 2015-04-29 Electrophoretics Ltd Materials and methods for diagnosis and treatment of alzheimers disease
JP7177702B2 (ja) * 2016-05-06 2022-11-24 ナノソミックス・インコーポレイテッド アルツハイマー病および他の神経変性障害のシナプスタンパク質バイオマーカーおよび鑑別診断
WO2017194995A1 (en) * 2016-05-11 2017-11-16 Institut National De La Sante Et De La Recherche Medicale (Inserm) A method for determining the temporal progression of a biological phenomenon and associated methods and devices
JPWO2018030252A1 (ja) * 2016-08-09 2019-06-20 大塚製薬株式会社 尿バイオマーカーを用いたアルツハイマー病の診断補助方法
JP6702836B2 (ja) * 2016-09-28 2020-06-03 ハルメク・ベンチャーズ株式会社 認知症判定得点算出装置及びそのプログラム
EP3532496A1 (en) 2016-10-28 2019-09-04 Banyan Biomarkers, Inc. Antibodies to ubiquitin c-terminal hydrolase l1 (uch-l1) and glial fibrillary acidic protein (gfap) and related methods
ES2600386B8 (es) * 2016-11-16 2017-08-04 Grifols Worldwide Operations Limited Método de diagnóstico in vitro de la enfermedad de alzheimer basado en el nivel redox de la albúmina en el líquido cefalorraquídeo
JP6359159B2 (ja) * 2017-07-25 2018-07-18 株式会社Ｍｃｂｉ 認知機能障害疾患のバイオマーカーおよび該バイオマーカーを用いる認知機能障害疾患の検出方法
WO2019143562A1 (en) * 2018-01-18 2019-07-25 University Of North Texas Health Science Center At Fort Worth Companion diagnostic for nsaids and donepezil for treating specific subpopulations of patients suffering from alzheimer's disease
WO2019175380A2 (en) * 2018-03-16 2019-09-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Antigenic peptides deriving from secretogranin v and uses thereof for the diagnosis and treatment of type 1 diabetes
CN112119310B (zh) 2018-03-16 2024-04-09 奎斯特诊断投资有限公司 通过质谱检测嗜铬粒蛋白a的方法
JP7437376B2 (ja) * 2018-07-19 2024-02-22 ジェネンテック，インコーポレーテッド マーカー分子に基づいて、アミロイド陽性認知症を罹患していると、または発症するリスクがあると個体を同定する方法、および関連する使用
EP3861352A4 (en) * 2018-10-04 2022-08-03 University of Manitoba NOVEL BIOMARKER FOR HUMAN ALZHEIMER'S DISEASE
US11621087B2 (en) 2019-09-24 2023-04-04 International Business Machines Corporation Machine learning for amyloid and tau pathology prediction
US11657189B2 (en) 2020-03-30 2023-05-23 Kyndryl, Inc. Object loss prevention using cognitive computing
JP7109499B2 (ja) * 2020-05-07 2022-07-29 一般社団法人脳と心の健康科学研究所 認知症判定得点算出装置及びそのプログラム
JPWO2022070798A1 (enExample) * 2020-09-29 2022-04-07
EP4269556A4 (en) * 2020-12-28 2024-11-13 MCBI, Inc. METHOD FOR GENERATING ASSESSMENT SUPPORT INFORMATION, SYSTEM FOR GENERATING ASSESSMENT SUPPORT INFORMATION AND INFORMATION PROCESSING DEVICE
CN115078570B (zh) * 2022-05-30 2024-05-28 郑州大学第一附属医院 Tau蛋白639位硫氰酸氨基酸修饰在快速质谱法检测阿尔茨海默症中的应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5506337A (en) 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5010175A (en) 1988-05-02 1991-04-23 The Regents Of The University Of California General method for producing and selecting peptides with specific properties
SE462454B (sv) 1988-11-10 1990-06-25 Pharmacia Ab Maetyta foer anvaendning i biosensorer
IE66205B1 (en) 1990-06-14 1995-12-13 Paul A Bartlett Polypeptide analogs
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
US6283761B1 (en) 1992-09-08 2001-09-04 Raymond Anthony Joao Apparatus and method for processing and/or for providing healthcare information and/or healthcare-related information
US5288514A (en) 1992-09-14 1994-02-22 The Regents Of The University Of California Solid phase and combinatorial synthesis of benzodiazepine compounds on a solid support
ATE242485T1 (de) 1993-05-28 2003-06-15 Baylor College Medicine Verfahren und massenspektrometer zur desorption und ionisierung von analyten
US5519134A (en) 1994-01-11 1996-05-21 Isis Pharmaceuticals, Inc. Pyrrolidine-containing monomers and oligomers
US5593853A (en) 1994-02-09 1997-01-14 Martek Corporation Generation and screening of synthetic drug libraries
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5525735A (en) 1994-06-22 1996-06-11 Affymax Technologies Nv Methods for synthesizing diverse collections of pyrrolidine compounds
US5549974A (en) 1994-06-23 1996-08-27 Affymax Technologies Nv Methods for the solid phase synthesis of thiazolidinones, metathiazanones, and derivatives thereof
US5569588A (en) 1995-08-09 1996-10-29 The Regents Of The University Of California Methods for drug screening
NZ516848A (en) 1997-06-20 2004-03-26 Ciphergen Biosystems Inc Retentate chromatography apparatus with applications in biology and medicine
CA2323638A1 (en) 1998-04-03 1999-10-14 Phylos, Inc. Addressable protein arrays
US6406921B1 (en) 1998-07-14 2002-06-18 Zyomyx, Incorporated Protein arrays for high-throughput screening
EP1123509B1 (en) * 1998-10-23 2004-12-29 EVOTEC Neurosciences GmbH Methods of diagnosing or prognosing alzheimer's disease
WO2000056934A1 (en) 1999-03-24 2000-09-28 Packard Bioscience Company Continuous porous matrix arrays
CA2368247A1 (en) 1999-04-27 2000-11-09 Ciphergen Biosystems, Inc. Probes for a gas phase ion spectrometer
CA2371738A1 (en) 1999-04-29 2000-11-09 Jody Beecher Sample holder with hydrophobic coating for gas phase mass spectrometers
AU779635B2 (en) 1999-10-27 2005-02-03 Health Discovery Corporation Methods and devices for identifying patterns in biological systems and methods for uses thereof
AU2001273675A1 (en) * 2000-07-03 2002-01-14 University Of South Florida Methods and assays for diagnosing alzheimer's disease
SG144731A1 (en) 2000-07-18 2008-08-28 Correlogic Systems Inc A process for discriminating between biological states based on hidden patterns from biological data
EP1355727A4 (en) 2000-11-16 2007-04-11 Ciphergen Biosystems Inc METHOD OF ANALYSIS OF MASS SPECTRUM
AU2002341488A1 (en) * 2001-05-09 2002-11-18 Biovision Ag Method for detecting progredient chronic dementia, and associated peptides and detection reagents
US7113896B2 (en) 2001-05-11 2006-09-26 Zhen Zhang System and methods for processing biological expression data
JP4264002B2 (ja) 2001-07-17 2009-05-13 バイオ−ラド ラボラトリーズ インコーポレイテッド ラテックスベース吸着チップ
CA2461529A1 (en) * 2001-09-25 2003-04-03 Immuno-Biological Laboratories Co., Ltd. Recombinant anti-osteopontin antibody and use thereof
US7842498B2 (en) 2001-11-08 2010-11-30 Bio-Rad Laboratories, Inc. Hydrophobic surface chip
US20030100016A1 (en) * 2001-11-23 2003-05-29 George Jackowski Complement C3 precursor biopolymer markers predictive of Alzheimers disease
EP1481244A4 (en) 2002-01-25 2008-07-02 Bio Rad Laboratories MONOMERS AND POLYMERS WITH ENERGY ABSORBENT GROUPS FOR USE IN THE DESORPTION / IONIZATION OF ANALYTES
US20020193950A1 (en) 2002-02-25 2002-12-19 Gavin Edward J. Method for analyzing mass spectra
AU2003253014A1 (en) * 2002-06-21 2004-01-06 Innogenetics N.V. Method for the diagnosis and differential diagnosis of neurological diseases
DK1535076T3 (da) * 2002-08-23 2008-11-24 Bayer Healthcare Ag Polypeptid-biomarkörer til diagnose af Alzheimers sygdom
US7632686B2 (en) * 2002-10-03 2009-12-15 Anderson Forschung Group High sensitivity quantitation of peptides by mass spectrometry
TWI552751B (zh) 2011-06-20 2016-10-11 Ｈ 朗德貝克公司 投予４－（（１ｒ，３ｓ）－６－氯－３－苯基－二氫茚－１－基）－１，２，２－三甲基－哌及其鹽用於治療精神分裂症的方法

Also Published As

Publication number Publication date
EP1694816B1 (en) 2013-08-28
WO2005047484A2 (en) 2005-05-26
US7794948B2 (en) 2010-09-14
JP5479379B2 (ja) 2014-04-23
US20110129920A1 (en) 2011-06-02
EP1694816A2 (en) 2006-08-30
EP2369347A1 (en) 2011-09-28
WO2005047484A3 (en) 2007-06-07
JP2007524847A (ja) 2007-08-30
JP2011085601A (ja) 2011-04-28
US20050244890A1 (en) 2005-11-03
EP2369348A1 (en) 2011-09-28
EP1694816A4 (en) 2008-08-20

Similar Documents

Publication Publication Date Title
JP4796967B2 (ja) アルツハイマー病のためのバイオマーカー
JP2007524847A5 (enExample)
Davidsson et al. The use of proteomics in biomarker discovery in neurodegenerative diseases
US20110313681A1 (en) Biomarkers for peripheral artery disease
KR20070043868A (ko) 암에 대한 혈소판 바이오마커
US20120172356A1 (en) Serum biomarkers for chagas disease
US7993868B2 (en) Saposin D and FAM3C are biomarkers for alzheimer's disease
US20130073308A1 (en) Methods of Detecting a Fragment of Neurosecretory Protein VGF for Diagnosing Alzheimer's Disease
EP1907838B1 (en) Fragment of neurosecretory protein vgf as a biomarker for alzheimer's disease
HK1110388B (en) Fragment of neurosecretory protein vgf as a biomarker for alzheimer's disease
Carrette et al. Proteomic Applications for Molecular Assessment of Alzheimer's Disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20071029

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20071029

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100722

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20101020

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20101027

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20110124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110311

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110609

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110704

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110801

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140805

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees